Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for individuals who suffer from psychiatric disorders, announced that Greenbrook TMS Neurohealth Centers, a NeuroStar Advanced Therapy provider organization with 82 treatment centers across the U.S., has installed its 100th NeuroStar system. This is a significant milestone in the availability of NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment for consumers. Greenbrook’s Matthews, North Carolina location joins the growing number of practices offering NeuroStar TMS.
NeuroStar is a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in depression. It offers clinical professionals real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment and making it a best-in-class treatment option. Greenbrook has been treating consumers with NeuroStar since 2011.
Since receiving U.S. Food and Drug Administration (FDA) clearance in 2008 as a safe and effective option for adults with Major Depressive Disorder (MDD), NeuroStar has been a trailblazer in the depression treatment space and is the number one TMS choice of doctors. In the last decade, more than 2.3 million NeuroStar treatments have been delivered across nearly 800 practice locations in the U.S., and its footprint continues to grow.
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for consumers who suffer from psychiatric disorders. The system is cleared by the FDA for the treatment of Major Depressive Disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance.
Operating through 85 company-operated treatment centers, Greenbrook is a leading provider organization of TMS, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 285,000 TMS treatments to over 8,000 individuals struggling with depression.
This was reported by NeuroStar Headquarters on September 4, 2019.
Contact information: Greenbrook TMS NeuroHealth Centers, 8450 Greensboro Drive, Suite 120, McLean, Virginia 22102; 855-940-4867; Website: www.greenbrooktms.com